Neuren Pharmaceuticals (ASX:NEU) announced top-line results from its Phase 2 clinical trial of NNZ-2591 in children with Phelan-McDermid syndrome. Significant improvement was observed by both clinicians and caregivers from treatment | ASX announcement: https://www.neurenpharma.com/pdf/f9ca13b8-b75f-4ff5-a5b7-1dcb75d547d6/P2-trial-shows-significant-improvements-in-PhelanMcDermid.pdf #shorts
No gainer or loser data available.
